Stocks and Investing Stocks and Investing
Wed, November 8, 2023
Tue, November 7, 2023

Charles Duncan Reiterated (AXSM) at Buy and Held Target at $108 on, Nov 7th, 2023


Published on 2024-10-28 07:23:32 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Reiterated "Axsome Therapeutics, Inc." (AXSM) at Buy and Held Target at $108 on, Nov 7th, 2023.

Charles has made no other calls on AXSM in the last 4 months.



There are 4 other peers that have a rating on AXSM. Out of the 4 peers that are also analyzing AXSM, 1 agrees with Charles's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jason Gerberry of "B of A Securities" Upgraded from Sell to Hold and Increased Target to $81 on, Tuesday, August 8th, 2023


These are the ratings of the 3 analyists that currently disagree with Charles


  • Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy and Held Target at $100 on, Monday, September 25th, 2023
  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $180 on, Tuesday, August 8th, 2023
  • David Amsellem of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $90 on, Tuesday, August 8th, 2023